Adamind buys Chinese company

Media mobile software provider Adamind Ltd. agreed to acquire Hong Kong-based SenseStream Ltd.for $2 million in cash and shares.

By AVI KRAWITZ
February 9, 2006 06:35

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Media mobile software provider Adamind Ltd. agreed to acquire Hong Kong-based SenseStream Ltd.for $2 million in cash and shares. Under the agreement, Adamind will pay $1m. in cash on completion the deal with the balance payable in shares by April 2007, dependent on certain targets being met during 2006. The deal is expected to close by the end of the month.An Adamind spokesperson said the company plans to merge all of SenseStream's activities within 12 months and to absorb its 10 workers into the Adamind structure. Ra'anana-based Adamind currently has 70 workers.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS